# 3×5 Partners

> 3×5 Partners is a VC fund in Portland backing Biotechnology and Medical. See 19 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Portland, United States
- Total investments: 19
- Last investment: Aug 2023
- Lead investor: 53%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/3x5-partners/
- Website: https://www.3x5partners.com/

3×5 Partners is a venture capital firm that focuses on innovations in the life science and resource-driven sectors. It identifies companies that reduce and evolve the consumption of the planet’s limited resources, including energy, food, waste, water, and other natural resources. It seeks opportunities in the life-science sector to improve patientoutcomes by developing innovations in biopharma and medical devices. It believes that these solution leaders will become some of the most valuable companies in the future.The firm was founded in 2011 and is headquartered in Portland, Oregon.

## Contacts

5 contacts available for 3×5 Partners. Shizune tracks 2 team members at 3×5 Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/3x5-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 37% |
| Medical | 4 | 21% |
| Health Care | 4 | 21% |
| Therapeutics | 3 | 16% |
| Manufacturing | 3 | 16% |

34 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 26% |
| Series A | 4 | 21% |
| Series C | 4 | 21% |
| Seed | 1 | 5% |
| Series D | 1 | 5% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anthony Arnerich | Managing Director and Founder | 2 | https://shizune.co/investors/profile/anthony-arnerich |
| Nicholas Walrod | Managing Director and Founder | 13 | https://shizune.co/investors/profile/nicholas-walrod |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kaleidoscope | Kaleidoscope designs, administers, and hosts branded scholarship and grant programs on a cloud-based marketplace. Its scholarship cloud marketplace connects scholarship funders to students. Kaleidoscope creates a friction-free marketplace connecting the most qualified candidates to personalized, curated scholarship opportunities.Founded byGregory Dehn in 2016, Kaleidoscope Group is headquartered in Minneapolis, Minnesota. | $2M | Series A | Aug 08, 2023 |  |
| Smart Wires | Smart Wires is an electrical and electronics company that specializes in grid optimization solutions that leverage its patented modular power flow control technology. The company provides solutions in the fields of transmission reliability, congestion management, and power flow control solutions.Smart Wires was founded in 2010 and headquarteredin San Francisco, California. | $5M | Post-IPO Equity | Nov 16, 2022 |  |
| Bonum Therapeutics | Bonum Therapeutics is creating a technology platform that can be used to treat a wide range of diseases, including cancer which is the company’s primary therapeutic area of focus—as well as metabolic diseases, immunology, and pain management. | $93M | Series A | Nov 15, 2022 |  |
| Fervo Energy | Fervo Energy is a next-generation geothermal developer generating clean power in new places. Fervo Energy commercializes proprietary technology to own, develop, and operate geothermal assets as the dispatchable foundation to a 100% clean energy future. | $138M | Series C | Aug 22, 2022 |  |
| Enzinc | An advanced battery developer delivering a zinc-based battery using NRL technology: a zinc metal nano-sponge that has the energy of Li-ion, is as cheap as lead acid, but is safer than both. | $4.5M | Seed | Jul 25, 2022 |  |
| Kaleidoscope | Kaleidoscope designs, administers, and hosts branded scholarship and grant programs on a cloud-based marketplace. Its scholarship cloud marketplace connects scholarship funders to students. Kaleidoscope creates a friction-free marketplace connecting the most qualified candidates to personalized, curated scholarship opportunities.Founded byGregory Dehn in 2016, Kaleidoscope Group is headquartered in Minneapolis, Minnesota. | $10M | Series A | Apr 04, 2022 |  |
| Koya Medical | Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases to increase movement, mobility, and personalized care that is unavailable with traditional compression therapy. | $26M | Series B | Feb 03, 2022 |  |
| Good Therapeutics | Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer,more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology. | $8M | Series B | Dec 30, 2021 |  |
| Claros Technologies | Claros Technologies is an environmental technology company that develops solutions for the detection, analysis, and destruction of per- and polyfluoroalkyl substances (PFAS). The company provides PFAS testing and analytical laboratory services, proprietary PFAS destruction technology, and regulatory compliance solutions for industrial, municipal,and government organizations. Its technologies are designed to help identify, manage, and permanently eliminate PFAS contamination from water, wastewater, and other materials through science-based environmental remediation solutions. | $5.5M | Series A | Aug 04, 2021 |  |
| Arch Oncology | Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses. | $105M | Series C | Apr 27, 2021 |  |

10 of 19 investments shown.

## Co-investors
- [3×5 Partners](https://shizune.co/investors/profile/3x5-partners-658c) — VC Fund, 19 deals together
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 8 deals together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 6 deals together
- [Digitalis Ventures](https://shizune.co/investors/profile/digitalis-ventures) — VC Fund, 4 deals together
- [Rally Ventures](https://shizune.co/investors/profile/rally-ventures) — VC Fund, 3 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does 3×5 Partners invest in?

3×5 Partners invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact 3×5 Partners?

Public channels for 3×5 Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at 3×5 Partners?

The team at 3×5 Partners includes Anthony Arnerich (Managing Director and Founder) and Nicholas Walrod (Managing Director and Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co